[go: up one dir, main page]

WO2007080598A3 - A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis. - Google Patents

A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis. Download PDF

Info

Publication number
WO2007080598A3
WO2007080598A3 PCT/IN2006/000008 IN2006000008W WO2007080598A3 WO 2007080598 A3 WO2007080598 A3 WO 2007080598A3 IN 2006000008 W IN2006000008 W IN 2006000008W WO 2007080598 A3 WO2007080598 A3 WO 2007080598A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
inhibiting
restenosis
neointimal proliferation
reducing neointimal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000008
Other languages
French (fr)
Other versions
WO2007080598A2 (en
Inventor
Baskaran Chandrasekar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/IN2006/000008 priority Critical patent/WO2007080598A2/en
Publication of WO2007080598A2 publication Critical patent/WO2007080598A2/en
Publication of WO2007080598A3 publication Critical patent/WO2007080598A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to a pharmaceutical composition for inhibiting / reducing neointimal proliferation. This pharmaceutical composition consists of diphenyleneiodonium and/or its chemical equivalents either alone or in combination with any pharmaceutically effective compound capable of preventing restenosis. This composition is administered locally into the wall of the coronary artery during the percutaneous coronary intervention procedure.
PCT/IN2006/000008 2006-01-10 2006-01-10 A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis. Ceased WO2007080598A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2006/000008 WO2007080598A2 (en) 2006-01-10 2006-01-10 A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2006/000008 WO2007080598A2 (en) 2006-01-10 2006-01-10 A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis.

Publications (2)

Publication Number Publication Date
WO2007080598A2 WO2007080598A2 (en) 2007-07-19
WO2007080598A3 true WO2007080598A3 (en) 2007-09-27

Family

ID=38256717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000008 Ceased WO2007080598A2 (en) 2006-01-10 2006-01-10 A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis.

Country Status (1)

Country Link
WO (1) WO2007080598A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305247B6 (en) 2013-09-20 2015-07-01 Ústav molekulární genetiky AV ČR, v.v.i. Pharmaceutical composition containing diphenyleneiodonium for treating diseases caused by parasites of Trypanosomatidae species

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623666A (en) * 1984-11-06 1986-11-18 Kennedy Thomas P Pharmacological applications of diphenylhalonium ion
US20020022022A1 (en) * 2000-05-19 2002-02-21 Yi Shi Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
US6849662B2 (en) * 1996-11-13 2005-02-01 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US20050215533A1 (en) * 2002-07-09 2005-09-29 Roberta Gottlieb Method to inhibit ischemia and reperfusion injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623666A (en) * 1984-11-06 1986-11-18 Kennedy Thomas P Pharmacological applications of diphenylhalonium ion
US6849662B2 (en) * 1996-11-13 2005-02-01 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US20020022022A1 (en) * 2000-05-19 2002-02-21 Yi Shi Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
US20050215533A1 (en) * 2002-07-09 2005-09-29 Roberta Gottlieb Method to inhibit ischemia and reperfusion injury

Also Published As

Publication number Publication date
WO2007080598A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2009005269A3 (en) Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
MX2009004681A (en) Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors.
WO2008092006A3 (en) Antimicrobial compositions
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
EP2099448A4 (en) Pharmaceutical composition for treatment and prevention of restenosis
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
MX2009006630A (en) 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors.
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
EP2137175A4 (en) Novel phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome
WO2008012666A3 (en) Treatment and prevention mucositis by anthocyanidin derivatives
WO2007120897A3 (en) Compositions and intraluminal devices for inhibiting vascular stenosis
IL188438A (en) Pharmacologically active benzofused five-membered heterocycles, or pharmaceutically acceptable salts and esters thereof and pharmaceutical compositions containing them and their use as inhibitors of catechol-o-methyltransferase (comt) enzyme
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
WO2008079873A3 (en) Thiazolyl compounds useful as kinase inhibitors
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2008009210A8 (en) Optical pure dihydropyrimidine compounds, their uses in the manufacture of a medicamnent for the treatment or the prevention of virosis diseases
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008125800A3 (en) Mmp activated vascular disrupting agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06711351

Country of ref document: EP

Kind code of ref document: A2